MedTrace Logo

A Study of XMT-1660 in Participants With Solid Tumors

NCT05377996 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 319

Last updated 2026-04-14

No results posted yet for this study

Summary

A Study of XMT-1660 in Solid Tumors

Conditions

Interventions

DRUG

XMT-1660

XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)

Sponsors & Collaborators

  • Mersana Therapeutics

    lead INDUSTRY

Principal Investigators

  • Robert Burger, MD · Mersana Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-15
Primary Completion
2026-12-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05377996 on ClinicalTrials.gov